These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 33661186)

  • 81. Strategies to overcome drug resistance using SHP2 inhibitors.
    Liu M; Gao S; Elhassan RM; Hou X; Fang H
    Acta Pharm Sin B; 2021 Dec; 11(12):3908-3924. PubMed ID: 35024315
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Structure, function, and pathogenesis of SHP2 in developmental disorders and tumorigenesis.
    Huang WQ; Lin Q; Zhuang X; Cai LL; Ruan RS; Lu ZX; Tzeng CM
    Curr Cancer Drug Targets; 2014; 14(6):567-88. PubMed ID: 25039348
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Prognostic genes in the tumor microenvironment in cervical squamous cell carcinoma.
    Pan XB; Lu Y; Huang JL; Long Y; Yao DS
    Aging (Albany NY); 2019 Nov; 11(22):10154-10166. PubMed ID: 31740624
    [TBL] [Abstract][Full Text] [Related]  

  • 84. The structure, regulation, and function of ZAP-70.
    Au-Yeung BB; Deindl S; Hsu LY; Palacios EH; Levin SE; Kuriyan J; Weiss A
    Immunol Rev; 2009 Mar; 228(1):41-57. PubMed ID: 19290920
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Differential Src family kinase activity requirements for CD3 zeta phosphorylation/ZAP70 recruitment and CD3 epsilon phosphorylation.
    Lysechko TL; Ostergaard HL
    J Immunol; 2005 Jun; 174(12):7807-14. PubMed ID: 15944285
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Use of mesothelin as a tumor-associated antigen in cervical squamous cell carcinoma.
    He Y; Zhao H; Li XM; Yin CH; Wu YM
    Gene; 2019 Mar; 690():30-37. PubMed ID: 30583024
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Small Molecule Inhibitor that Stabilizes the Autoinhibited Conformation of the Oncogenic Tyrosine Phosphatase SHP2.
    Wu X; Xu G; Li X; Xu W; Li Q; Liu W; Kirby KA; Loh ML; Li J; Sarafianos SG; Qu CK
    J Med Chem; 2019 Feb; 62(3):1125-1137. PubMed ID: 30457860
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Identification, recombinant expression and immunological study of Lja-SHP2 in Lampetra japonica.
    Li X; Qu CM; Han YL; Liu X; Li QW
    Yi Chuan; 2020 Feb; 42(2):183-193. PubMed ID: 32102775
    [TBL] [Abstract][Full Text] [Related]  

  • 89. New approaches to prevent LEOPARD syndrome-associated cardiac hypertrophy by specifically targeting Shp2-dependent signaling.
    Schramm C; Edwards MA; Krenz M
    J Biol Chem; 2013 Jun; 288(25):18335-44. PubMed ID: 23673659
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Inhibition of Shp2 suppresses mutant EGFR-induced lung tumors in transgenic mouse model of lung adenocarcinoma.
    Schneeberger VE; Ren Y; Luetteke N; Huang Q; Chen L; Lawrence HR; Lawrence NJ; Haura EB; Koomen JM; Coppola D; Wu J
    Oncotarget; 2015 Mar; 6(8):6191-202. PubMed ID: 25730908
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Acylglycerol kinase is over-expressed in early-stage cervical squamous cell cancer and predicts poor prognosis.
    Sun F; Xiong Y; Zhou XH; Li Q; Xiao L; Long P; Li LJ; Cai MY; Wei YX; Ma YL; Yu YH
    Tumour Biol; 2016 May; 37(5):6729-36. PubMed ID: 26662108
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Negative signaling contributes to T-cell anergy in trauma patients.
    Bandyopadhyay G; De A; Laudanski K; Li F; Lentz C; Bankey P; Miller-Graziano C
    Crit Care Med; 2007 Mar; 35(3):794-801. PubMed ID: 17255857
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Tyrosine phosphatase SHP2 inhibitors in tumor-targeted therapies.
    Song Z; Wang M; Ge Y; Chen XP; Xu Z; Sun Y; Xiong XF
    Acta Pharm Sin B; 2021 Jan; 11(1):13-29. PubMed ID: 33532178
    [TBL] [Abstract][Full Text] [Related]  

  • 94. The tyrosine phosphatase SHP2 is required for cell transformation by the receptor tyrosine kinase mutants FIP1L1-PDGFRα and PDGFRα D842V.
    Noël LA; Arts FA; Montano-Almendras CP; Cox L; Gielen O; Toffalini F; Marbehant CY; Cools J; Demoulin JB
    Mol Oncol; 2014 May; 8(3):728-40. PubMed ID: 24618081
    [TBL] [Abstract][Full Text] [Related]  

  • 95. A novel partially open state of SHP2 points to a "multiple gear" regulation mechanism.
    Tao Y; Xie J; Zhong Q; Wang Y; Zhang S; Luo F; Wen F; Xie J; Zhao J; Sun X; Long H; Ma J; Zhang Q; Long J; Fang X; Lu Y; Li D; Li M; Zhu J; Sun B; Li G; Diao J; Liu C
    J Biol Chem; 2021; 296():100538. PubMed ID: 33722610
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Targeting the SHP2 phosphatase promotes vascular damage and inhibition of tumor growth.
    Wang Y; Salvucci O; Ohnuki H; Tran AD; Ha T; Feng JX; DiPrima M; Kwak H; Wang D; Yu Y; Kruhlak M; Tosato G
    EMBO Mol Med; 2021 Jul; 13(7):e14089. PubMed ID: 34102002
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Tyrosine phosphatase
    Chen X; Keller SJ; Hafner P; Alrawashdeh AY; Avery TY; Norona J; Zhou J; Ruess DA
    Front Immunol; 2024; 15():1340726. PubMed ID: 38504984
    [TBL] [Abstract][Full Text] [Related]  

  • 98. SHP2 is involved in the occurrence, development and prognosis of cancer.
    Li S; Qu J; Wang X; Zou Q; Li C
    Oncol Lett; 2023 Sep; 26(3):393. PubMed ID: 37600341
    [TBL] [Abstract][Full Text] [Related]  

  • 99. The screening of compounds regulating PD-L1 transcriptional activity in a cell functional high-throughput manner.
    Zhang L; Li H; Liu J; Sun G; Tang X; Xu S; Zhang L; Zhang W; Ai B
    Cancer Med; 2023 Apr; 12(8):9815-9825. PubMed ID: 36965083
    [TBL] [Abstract][Full Text] [Related]  

  • 100.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.